TP53 and neoplasm: The first-in-class WEE1 inhibitor AZD1775 (adavosertib, MK-1775) has been shown to sensitize p53-deficient tumor cells to DNA-damaging chemotherapeutic agents in vitro and in vivo [7, 8] and is efficacious in multiple NE cancers including neuroblastoma [9], small cell lung cancer [10], and medulloblastoma [11].